Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas

Seung Mo Hong, Ang Li, Kelly Olino, Christopher L. Wolfgang, Joseph M. Herman, Richard D. Schulick, Christine Iacobuzio-Donahue, Ralph H. Hruban, Michael Goggins

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Only a minority of patients who undergo surgical resection for pancreatic ductal adenocarcinoma are cured. Since patient outcome is not reliably predicted using pathological factors (tumor stage, differentiation, and resection margin status) alone, markers of tumor behavior are needed. One candidate predictor of pancreatic cancer outcome is E-cadherin status. CDH1 is a tumor suppressor gene encoding an important cell adhesion molecule (E-cadherin). The aim of this study was to determine if, among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma, loss of E-cadherin expression was an independent predictor of poor outcome. We examined patterns of loss of E-cadherin by immunohistochemistry in tissue microarrays of 329 surgically resected pancreatic ductal adenocarcinomas. E-cadherin expression was then correlated with outcome. Kaplan-Meier analysis and Cox proportional hazards regression modeling were used to assess the mortality risk. One hundred forty-one pancreatic adenocarcinomas (43%) had partial or complete loss of E-cadherin expression within the analyzed tissue cores. In most instances (134 cases, 41%), this loss was partial. Patients whose pancreatic adenocarcinomas had either complete loss (n=7; median survival, 5.5 months) or partial loss (n=134; 12.7 months) of E-cadherin expression had significantly worse median survival than those with uniformly intact E-cadherin expression (n=188; 18.5 months) by univariate (P=0.002) and multivariate (P=0.006) analyses. In subgroup analysis, patients with poorly differentiated cancers had a worse prognosis if their cancers had partial loss of E-cadherin expression (P=0.02). Among patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma, partial loss of tumoral E-cadherin expression is an independent predictor of poor outcome.

Original languageEnglish (US)
Pages (from-to)1237-1247
Number of pages11
JournalModern Pathology
Volume24
Issue number9
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Cadherins
Adenocarcinoma
Pancreaticoduodenectomy
Neoplasms
Survival
Kaplan-Meier Estimate
Cell Adhesion Molecules
Tumor Biomarkers
Tumor Suppressor Genes
Pancreatic Neoplasms
Immunohistochemistry
Mortality

Keywords

  • Adenocarcinoma
  • E-cadherin
  • epithelial mesenchymal transition
  • pancreas
  • prognosis
  • survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Hong, S. M., Li, A., Olino, K., Wolfgang, C. L., Herman, J. M., Schulick, R. D., ... Goggins, M. (2011). Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Modern Pathology, 24(9), 1237-1247. https://doi.org/10.1038/modpathol.2011.74

Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. / Hong, Seung Mo; Li, Ang; Olino, Kelly; Wolfgang, Christopher L.; Herman, Joseph M.; Schulick, Richard D.; Iacobuzio-Donahue, Christine; Hruban, Ralph H.; Goggins, Michael.

In: Modern Pathology, Vol. 24, No. 9, 09.2011, p. 1237-1247.

Research output: Contribution to journalArticle

Hong, SM, Li, A, Olino, K, Wolfgang, CL, Herman, JM, Schulick, RD, Iacobuzio-Donahue, C, Hruban, RH & Goggins, M 2011, 'Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas', Modern Pathology, vol. 24, no. 9, pp. 1237-1247. https://doi.org/10.1038/modpathol.2011.74
Hong, Seung Mo ; Li, Ang ; Olino, Kelly ; Wolfgang, Christopher L. ; Herman, Joseph M. ; Schulick, Richard D. ; Iacobuzio-Donahue, Christine ; Hruban, Ralph H. ; Goggins, Michael. / Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. In: Modern Pathology. 2011 ; Vol. 24, No. 9. pp. 1237-1247.
@article{ebd49802416743e2986981cac76401cc,
title = "Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas",
abstract = "Only a minority of patients who undergo surgical resection for pancreatic ductal adenocarcinoma are cured. Since patient outcome is not reliably predicted using pathological factors (tumor stage, differentiation, and resection margin status) alone, markers of tumor behavior are needed. One candidate predictor of pancreatic cancer outcome is E-cadherin status. CDH1 is a tumor suppressor gene encoding an important cell adhesion molecule (E-cadherin). The aim of this study was to determine if, among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma, loss of E-cadherin expression was an independent predictor of poor outcome. We examined patterns of loss of E-cadherin by immunohistochemistry in tissue microarrays of 329 surgically resected pancreatic ductal adenocarcinomas. E-cadherin expression was then correlated with outcome. Kaplan-Meier analysis and Cox proportional hazards regression modeling were used to assess the mortality risk. One hundred forty-one pancreatic adenocarcinomas (43{\%}) had partial or complete loss of E-cadherin expression within the analyzed tissue cores. In most instances (134 cases, 41{\%}), this loss was partial. Patients whose pancreatic adenocarcinomas had either complete loss (n=7; median survival, 5.5 months) or partial loss (n=134; 12.7 months) of E-cadherin expression had significantly worse median survival than those with uniformly intact E-cadherin expression (n=188; 18.5 months) by univariate (P=0.002) and multivariate (P=0.006) analyses. In subgroup analysis, patients with poorly differentiated cancers had a worse prognosis if their cancers had partial loss of E-cadherin expression (P=0.02). Among patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma, partial loss of tumoral E-cadherin expression is an independent predictor of poor outcome.",
keywords = "Adenocarcinoma, E-cadherin, epithelial mesenchymal transition, pancreas, prognosis, survival",
author = "Hong, {Seung Mo} and Ang Li and Kelly Olino and Wolfgang, {Christopher L.} and Herman, {Joseph M.} and Schulick, {Richard D.} and Christine Iacobuzio-Donahue and Hruban, {Ralph H.} and Michael Goggins",
year = "2011",
month = "9",
doi = "10.1038/modpathol.2011.74",
language = "English (US)",
volume = "24",
pages = "1237--1247",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas

AU - Hong, Seung Mo

AU - Li, Ang

AU - Olino, Kelly

AU - Wolfgang, Christopher L.

AU - Herman, Joseph M.

AU - Schulick, Richard D.

AU - Iacobuzio-Donahue, Christine

AU - Hruban, Ralph H.

AU - Goggins, Michael

PY - 2011/9

Y1 - 2011/9

N2 - Only a minority of patients who undergo surgical resection for pancreatic ductal adenocarcinoma are cured. Since patient outcome is not reliably predicted using pathological factors (tumor stage, differentiation, and resection margin status) alone, markers of tumor behavior are needed. One candidate predictor of pancreatic cancer outcome is E-cadherin status. CDH1 is a tumor suppressor gene encoding an important cell adhesion molecule (E-cadherin). The aim of this study was to determine if, among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma, loss of E-cadherin expression was an independent predictor of poor outcome. We examined patterns of loss of E-cadherin by immunohistochemistry in tissue microarrays of 329 surgically resected pancreatic ductal adenocarcinomas. E-cadherin expression was then correlated with outcome. Kaplan-Meier analysis and Cox proportional hazards regression modeling were used to assess the mortality risk. One hundred forty-one pancreatic adenocarcinomas (43%) had partial or complete loss of E-cadherin expression within the analyzed tissue cores. In most instances (134 cases, 41%), this loss was partial. Patients whose pancreatic adenocarcinomas had either complete loss (n=7; median survival, 5.5 months) or partial loss (n=134; 12.7 months) of E-cadherin expression had significantly worse median survival than those with uniformly intact E-cadherin expression (n=188; 18.5 months) by univariate (P=0.002) and multivariate (P=0.006) analyses. In subgroup analysis, patients with poorly differentiated cancers had a worse prognosis if their cancers had partial loss of E-cadherin expression (P=0.02). Among patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma, partial loss of tumoral E-cadherin expression is an independent predictor of poor outcome.

AB - Only a minority of patients who undergo surgical resection for pancreatic ductal adenocarcinoma are cured. Since patient outcome is not reliably predicted using pathological factors (tumor stage, differentiation, and resection margin status) alone, markers of tumor behavior are needed. One candidate predictor of pancreatic cancer outcome is E-cadherin status. CDH1 is a tumor suppressor gene encoding an important cell adhesion molecule (E-cadherin). The aim of this study was to determine if, among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma, loss of E-cadherin expression was an independent predictor of poor outcome. We examined patterns of loss of E-cadherin by immunohistochemistry in tissue microarrays of 329 surgically resected pancreatic ductal adenocarcinomas. E-cadherin expression was then correlated with outcome. Kaplan-Meier analysis and Cox proportional hazards regression modeling were used to assess the mortality risk. One hundred forty-one pancreatic adenocarcinomas (43%) had partial or complete loss of E-cadherin expression within the analyzed tissue cores. In most instances (134 cases, 41%), this loss was partial. Patients whose pancreatic adenocarcinomas had either complete loss (n=7; median survival, 5.5 months) or partial loss (n=134; 12.7 months) of E-cadherin expression had significantly worse median survival than those with uniformly intact E-cadherin expression (n=188; 18.5 months) by univariate (P=0.002) and multivariate (P=0.006) analyses. In subgroup analysis, patients with poorly differentiated cancers had a worse prognosis if their cancers had partial loss of E-cadherin expression (P=0.02). Among patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma, partial loss of tumoral E-cadherin expression is an independent predictor of poor outcome.

KW - Adenocarcinoma

KW - E-cadherin

KW - epithelial mesenchymal transition

KW - pancreas

KW - prognosis

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=80052413002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052413002&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2011.74

DO - 10.1038/modpathol.2011.74

M3 - Article

C2 - 21552209

AN - SCOPUS:80052413002

VL - 24

SP - 1237

EP - 1247

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 9

ER -